News
C-RAD and SeeTreat partner to co-develop personalised radiotherapy for every patient in every clinic
C-RAD and SeeTreat partner to co-develop personalised radiotherapy for every patient in every clinic UPPSALA, Sweden/SYDNEY, Australia – September 29, 2026 – C-RAD (publ) the global leader in surface-guided radiation therapy (SGRT), and SeeTreat Pty Ltd, a pioneer in the adaptive decision support radiotherapy (ART) software, today confirm a partnership to co-develop more connected, intelligent, and patient-centric radiotherapy workflows.
Read more
ABC Radio National interview - Changing Australia: Paul Keall and innovating with radiotherapy
SeeTreat co-founder Professor Paul Keall speaks with Sally Sara on innovating with radiotherapy. Prof Keall writes of this interview: "It was an honour to be invited to contribute to the ABC's Changing Australia series hosted by Sally Sara. On the question of how to bring innovations in radiotherapy to large numbers of patients I am proud that we at SeeTreat are doing just that: developing accessible technology to ensure that the radiation treatment is personalised to the patient throughout their course of therapy."
Read more
SeeTreat's ART.1-US Software is FDA Cleared for clinical use in the USA
SYDNEY, May 18, 2026 /PRNewswire/ -- SeeTreat's ART.1-US software delivering automated adaptive decision support for every patient at every treatment is cleared for use in the USA. From today, US clinics with Varian or Elekta CT linear accelerators, will be able to access daily evaluations of radiotherapy dose to patients' changing anatomy. With ART.1-US, clinical teams can now decide the right time for a new radiotherapy plan in 95+ seconds[1], and download supporting clinical documentation.
Read more
GenesisCare and SeeTreat to bring personalised Offline Adaptive Monitoring to more than 40 radiation oncology centres across Australia
SYDNEY, May 14, 2026 /PRNewswire/ -- Leading Australian cancer care provider, GenesisCare, is pleased to be collaborating with SeeTreat to enable suitable cancer patients access to the latest technology in offline adaptive treatment assessment. SeeTreat's ART.1 software will be rolled out at GenesisCare from July 2026 to support automated, adaptive treatment evaluation for eligible patients.
Read more
Michelle JoinerWriter, G3 Medical Marketing7 November 2025SeeTreat's ART.1 is now CE Marked under EU MDR - Bringing Adaptive Radiotherapy to Every Clinic
SeeTreat announced today that its offline adaptive radiotherapy software, ART.1, has received CE Mark certification under the European Union Medical Device Regulation and is now available for clinical use across the European Union.
Read more
Prof. Jarad MartinSeeTreat CMO, practicing radiation oncologist (MBChB BSc PhD DMed FRANZCR GAustMS)19 October 2025ART.1: Seamless, Safe, and Easy: A Radiation Oncologist's Perspective
Offline ART Remains the Go-To Approach As a radiation oncologist, I've seen the challenges of offline adaptive radiotherapy (ART) firsthand. Every department seems to have its own “secret sauce” for when to adapt a plan, and quite honestly, it all seems a little bit heuristic about what's being applied. That variability told me one thing: there's no universal standard, and that can make consistent, high-quality care difficult to achieve.
Read more
Adam ManoliChief Commercial Officer27 June 2025What the Radiation Oncology Community is Saying About Adaptive Radiotherapy (ART): Insights from SeeTreat's LinkedIn Polls
Over the past few weeks, SeeTreat turned to LinkedIn to gather insights from the radiation oncology community on current practices and perspectives surrounding Adaptive Radiotherapy (ART). The results reveal both growing interest and the practical challenges of implementation.
Read more
Adam ManoliChief Commercial Officer21 May 2025What's Holding Back Adaptive Radiation Therapy? A Look at the Tools Needed.
What's Holding Back Adaptive Radiation Therapy? A Look at the Tools Needed Adaptive radiation therapy (ART) holds immense potential to improve cancer care by reducing treatment-related toxicity and lowering recurrence rates. However, despite its clear clinical and economic benefits, adoption remains limited. In Australia, for example, only about 3% of patients currently receive adaptive radiotherapy, leaving 97% without access to this enhanced approach. A key reason is the significant number of technical tools, processes, and human resources required to deliver ART effectively.
Read more
Michelle JoinerWriter, G3 Medical Marketing30 April 2025SeeTreat to Launch ART.1 to Support Adaptive Radiotherapy at ESTRO 2025
SeeTreat will debut its first clinical product, ART.1, at Booth 820 during ESTRO 2025 in Vienna. ART.1 is a software as a medical device that delivers objective, evidence-based decision support for adaptive treatment re-planning in patients undergoing radiotherapy. ART.1 automatically calculates delivered dose and propagates daily contours based on each patient's volumetric imaging, while displaying and reporting key clinical metrics. Running silently in the background, ART.1 prioritizes only the patient cases needing attention—allowing clinical teams to focus their time where it matters most. The software adds efficient, adaptive-quality treatment capabilities on any standard linear accelerator—without hardware upgrades or workflow disruption.
Read more
Expanding Global Access to Offline Adaptive Radiotherapy
Prof. Keall discusses a game-changing approach to making offline adaptive evaluation more accessible to everyone. This is a unique opportunity to learn from a global leader in radiation oncology research and watch the live Q&A session following the presentation.
Read more
Breaking Down Adaptive Radiation Therapy: A Call to Action
Adaptive Radiation Therapy (ART) has been a concept in radiation oncology for nearly three decades, yet its widespread implementation remains limited. The foundation of ART can be traced back to a pivotal paper published 28 years ago by Di Yan and colleagues at William Beaumont Hospital in Michigan. Their study demonstrated the potential of using multiple CT scans to refine treatment planning for individual patients. Despite the clear benefits of this approach, ART is still not routinely available in a fast, automated, and cost-effective manner. This underscores the urgent need to expand access to this transformative technology.
Read more
Unlocking the Full Potential of Adaptive Radiotherapy
Imagine a world where every cancer patient has access to life-saving radiation therapy. Adaptive Radiotherapy (ART) ensures treatment plans stay aligned with a patient's changing anatomy. However, widespread adoption remains a challenge—ART is traditionally expensive, resource-intensive, and requires specialized equipment, advanced software, and significant clinical oversight. Identifying and executing a replan can take hours or even days, delaying critical treatment.
Read more
Hannah CrossmanOperations Manager12 February 2025International Women in STEM Day
Today, on International Women in STEM Day, we proudly acknowledge the incredible women making groundbreaking contributions in the fields of science, technology, engineering, and mathematics—especially in the critical intersection of healthcare and technology. At SeeTreat, we are inspired by the brilliant women on our team who are driving innovation in medical software engineering. As a female founded business, we are committed to fostering an environment where women thrive, lead, and push the boundaries of wha's possible. For more information on some of the incredible women working at SeeTreat, visit our About Us (https://www.seetreatmedical.com/about-us) page.
Read more
CUREator+ grant
SeeTreat is pleased to announce we are the recipient of the CUREator+ Grant to clinically evaluate and commercialise a new medical technology to enhance breast cancer radiation therapy treatments. The product is expected to improve treatment effectiveness and mitigate risks of complications due to radiation exposure to the heart and other non-target tissues.
Read more
SeeTreat receives CUREator+ grant
We are proud to be part of eight Australian startups developing innovations with the potential to save lives and improve wellbeing receiving grants totalling $18.5 million thanks to the first CUREator+ funding round 🎉
Read more
SeeTreat welcomes new Board directors
SeeTreat, a software medical device company with a vision to 'turn on the light' for oncology treatments enabling affordable personalised and precise treatment for every patient, is pleased to announce new Board directors as SeeTreat prepares for commercial release of its first products to clinics. We welcome Dr Richard Hausmann, Associate Professor Tee Lim and Dr Shane La Bianca to our Board from October 2024. They will join existing executive Board members Dr Trang Nguyen (CEO and Co-Founder), Professor Paul Keall (Co-Founder) and Antonia Dalton (Chief Strategy Officer).
Read more
ICON Writers 29 August 2024Icon Group partners with SeeTreat to pioneer precision radiation therapy
Icon Group (https://icongroup.global/en/news/2024-08-29/icon-group-partners-with-seetreat-medical-to-pioneer-precision-radiotherapy/) (Icon), will be the first to partner with SeeTreat to lead innovation in precision radiation therapy treatment. SeeTreat is a unique Australian medical software start-up who is solving real clinical problems in radiotherapy through software solutions that are high quality, efficient and patient and user centric.
Read more
Hannah CrossmanOperations Manager4 August 2024SeeTreat's New Director: Antonia Dalton
We are pleased to announce the appointment of Antonia Dalton as SeeTreat's Chief Strategy Officer to our company board. Antonia brings a wealth of commercial, financial, and legal expertise, complementing the skills of our existing team.
Read more
SeeTreat partners with Lumonus
Lumonus (https://www.lumonus.com/) and SeeTreat are pleased to announce their partnership to improve personalisation and precision in radiotherapy treatment in the USA in 2024. Combining Lumonus AI Product with SeeTreat's software solutions means ALL patients can be assured of receiving radiotherapy to the right place at the right time despite changes in tumour size or shape and anatomy over the course of treatment. Our combined software solutions are designed to be user centric, efficient and accessible to all. Our teams are excited to be joining forces to innovate for the benefit of millions of cancer patients each year.
Read more
SeeTreat and ImageX NHMRC Grant
SeeTreat is pleased to announce that, in partnership with the Image X Institute at the University of Sydney, we have successfully received a three-year NHMRC Development Grant to build an exciting new AI medical device.
Read more
SeeTreat at ESTRO 2024
We are thrilled to announce that SeeTreat will be well represented at ESTRO 2024 in Glasgow. Our CEO, Dr. Trang Nguyen, CPO, Dr. Sean Pollock, Director of Clinical Research, Prof. Paul Keall, and Dr Jeremy Booth will be in attendance from the 3rd to the 7th of May.
Read more
SeeTreat has raised seed funding
SeeTreat has raised seed funding of $700k! This significant milestone will support development and commercialisation of our products in Australia, the USA and Europe in early 2024. Our first products will improve patient outcomes by personalising and improving precision in radiotherapy treatment. Watch this space!
Read more